Ocular Therapeutix, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 15.08 million compared to USD 11.97 million a year ago. Net loss was USD 0.516 million compared to USD 24.19 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.31 a year ago. Diluted loss per share from continuing operations was USD 0.25 compared to USD 0.31 a year ago.
For the nine months, revenue was USD 43.64 million compared to USD 37.42 million a year ago. Net loss was USD 51.52 million compared to USD 55.5 million a year ago. Basic loss per share from continuing operations was USD 0.66 compared to USD 0.72 a year ago. Diluted loss per share from continuing operations was USD 0.77 compared to USD 0.73 a year ago.